Abstract
9651 Background: PDGFR-β and c-kit expression have been described in EOC and imatinib is an inhibitor of both. A phase II clinical trial with proteomic signal pathway profiling is underway to elucidate both the clinical and biological activity of this new agent in EOC. Methods: Patients with relapsed or refractory EOC and no more than 4 prior regimens received imatinib at 400 mg bid; the starting dose was lowered to 600 mg daily due to toxicity. Patients were treated continuously in 28 day cycles and examined every 4 weeks, with imaging every 8 weeks. Tumors were biopsied prior to and after 4 weeks of treatment. Cytokine and growth factor concentrations were measured by ELISA in plasma and fluid samples. Results: Sixteen patients with a median of 4 prior regimens have been enrolled with 15 evaluable. Seven patients (47%) started treatment at 400 mg bid; 4 withdrew within 1 month. The remainder (9) started at 600 mg qd. Five patients (33%) without evidence of disease progression experienced unacceptable to...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
